Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis.

ABSTRACT:

Background/aims

We aimed to investigate the oral beclomethasone dipropionate's (BDP) efficacy as an add-on therapy and to clarify the predictive factor for response to oral BDP in Korean ulcerative colitis (UC) patients.

Methods

Patients with a stable concomitant drug regimen with exposure to oral BDP (5 mg/day) within 30 days before BDP initiation were included. Partial Mayo score (pMS) was used to evaluate response to oral BDP. Clinical remission (CREM) was defined as a post-treatment pMS ≤ 1 point. Clinical response (CRES) was defined as an at least 2-point decrease in post-treatment pMS and an at least 30% decrease from baseline pMS. Patients without CREM or CRES were considered nonresponders (NRs).

Results

Of all, 37 showed CREM, 19 showed CRES, and 44 were NRs.

SUBMITTER: Kim K 

PROVIDER: S-EPMC9666248 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature